AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03239821 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VIPUN Balloon Catheter 0.1 inflated
Description: VIPUN Balloon Catheter 0.1 inflated
Study NCT03509350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
Study NCT03509350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Study NCT03509350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Study NCT03509350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C Placebo
Description: A placebo to match intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
Study NCT03509350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiamine Placebo
Description: A placebo to match intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
Study NCT03509350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone Placebo
Description: A placebo to match intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge. Steroids will be used when clinically indicated.
Study NCT03798821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (100MG)
Description: six weeks of consumption
Study NCT03798821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (300MG)
Description: six weeks of consumption
Study NCT03798821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin and sucrose (PLACEBO)
Description: six weeks of consumption
Study NCT00649532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Tablets 24 mg
Description: 24mg, single dose fasting
Study NCT00649532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran® Tablets 24 mg
Description: 24mg, single dose fasting
Study NCT02983682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Infusion
Description: Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
Study NCT04529759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Powdered partially hydrolyzed whey (WPH) based formula with an oligosaccharide
Study NCT04529759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Powdered partially hydrolyzed whey (WPH) based formula with oligosaccharides blend
Study NCT04373031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized anti-PD-1 mAb of the IgG4/kappa isotype with a stabilizing S228P sequence alteration in the Fc region.
Study NCT04373031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX 2
Description: IRX-2, is a cell-derived biologic with multiple active cytokine components that acts on multiple cell types of the immune system including T cells, dendritic cells and natural killer cells.
Study NCT01018875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: Subjects will take 4 capsules once daily for 12 weeks.
Study NCT01018875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: Subjects will take 4 capsules once daily for 12 weeks.
Study NCT01018875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will take 4 capsules once daily for 12 weeks.
Study NCT04429178 — intervention group
Intervention type: OTHER
Intervention: ultrasound
Description: portal vein pulsatility fraction (percent) measured with ultrasound
Study NCT02305355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-acids ethylesters 90 4g
Study NCT02305355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin
Study NCT02305355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin
Study NCT01866007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (lyophilized formulation)
Description: Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
Study NCT01866007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (liquid formulation with PFS-U)
Description: Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
Study NCT01866007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (liquid formulation with PFS FID)
Description: Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
Study NCT01866007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (liquid formulation)
Description: Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
Study NCT00723970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Extended Release
Description: Quetiapine XR, 150-300 mg QHS, for 8 weeks
Study NCT00429858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)
Study NCT00429858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
Study NCT00097760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
Study NCT00097760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab, 300 mg IV infusion, every 4 weeks for up to 20 weeks.
Study NCT00097760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
Study NCT03174132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Perlane Lidocaine
Description: Intradermal injection
Study NCT03174132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Perlane
Description: Intradermal injection
Study NCT03031301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrant capsule
Description: One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.
Study NCT03031301 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham capsule
Description: One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.
Study NCT00514865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2333Ms Experimental 2
Description: 5-10 mg QD(once a day) for 8 weeks
Study NCT00514865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg QD(once a day) for 8 weeks
Study NCT00514865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2333Ms Experimental 1
Description: 1-2 mg QD(once a day) for 8 weeks
Study NCT00907400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: oral tablet
Study NCT00907400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: oral tablet
Study NCT03616938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation
Description: 2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines
Study NCT03389035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CARCIK-CD19
Description: Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene
Study NCT00896311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Nitroglycerin
Description: IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
Study NCT00896311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
Study NCT00969449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium, (BAY H6689)
Description: One dose of Naproxen sodium extended release 660 mg under fasting conditions
Study NCT00969449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprelan, (BAY H6689)
Description: One dose of Naprelan 500 mg (2 tablets) under fasting conditions
Study NCT03729492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CTEPH/CTED work-up
Description: Patients diagnosed with acute pulmonary embolism (PE) in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent PE related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a V/Q-scan. If a V/Q mismatch is present, the patient will be referred to a full work-up for CTEPH/CTED.
Study NCT04884230 — intervention group
Intervention type: PROCEDURE
Intervention: Oversewing
Description: Oversewing of the gastric remnant
Study NCT01451710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone or Prednisolone
Description: daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
Study NCT02499068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
Study NCT00397826 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MK0733
Description: Duration of Treatment: 12 Weeks
Study NCT01849172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Stick adhesive tapes to all points. For ST25, EX-CA1 and RN4, insert the needle vertically through the pads and the skin, and then slowly and vertically penetrate through the layer of fatty tissue, into the muscles of the abdominal wall .For RN4, manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times. Insert the needle vertically at SP6 to a depth of 1 cm. Manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times to reach de-qi. Put the electric stimulator on the pair of EX-CA1 and ST25 points with a dilatational wave, 10/50 Hz, 0.5-1.0mA. To turn on the current intensity till the abdomen shivers. The same manipulation methods for RN4 and SP6 will be given every 10 minutes (3 times in all).
Study NCT01849172 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: Non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides) are used.P1 and P3 are at the sites 1 cm (outward in horizontal direction) proximate to RN4 and ST25 respectively. P2 is 2 cm (outward in horizontal direction) proximate to EX-CA1. P4 is at the middle site of the spleen meridian and the kidney meridian (backward in horizontal direction proximate to SP6).~Stick adhesive tapes to all points. Blunt needles will be used to be inserted to but not piercing the skin. Even lifting, thrusting and twisting manipulation methods will be given for each non-point for 3 times. Put the sham electric stimulator on the pair of P2 and P3 with the same parameters as the acupuncture group. But there is no current intensity actually.
Study NCT03401528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500 is an investigational drug.
Study NCT03401528 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00825565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alwextin cream
Description: Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.
Study NCT00525395 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Sequential phototherapy
Description: Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
Study NCT00525395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous phototherapy
Description: Group B: 6 months non-stop treatment.
Study NCT04283695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7 or [14C] GX-I7
Description: IM GX-I7 or IV/IM microdose of GX-I7
Study NCT01598038 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Blood sample
Description: Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation
Study NCT03236558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Ten cc of peripheral blood will be taken from patients and healthy controls as soon as possible after T1D diagnosis of the former.
Study NCT00797732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Study NCT00797732 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Study NCT02956161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation of up-phase of sleep slow oscillation
Study NCT02956161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Random stimulation of up phase of sleep slow oscillation
Study NCT02956161 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No stimulation
Study NCT01789970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER
Description: During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Study NCT01789970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocodone ER
Description: During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Study NCT01789970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Study NCT00927771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelaic acid gel
Description: azelaic acid 15% gel twice a day for 6 months
Study NCT00927771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroquinone cream
Description: hydroquinone 4% cream twice a day for 6 months
Study NCT03597932 — intervention group
Intervention type: DEVICE
Intervention: standardized handover checklist
Description: Following a review of relevant literatures and guidelines, a checklist consisting of the various key items necessary for giving continuing and safe intraoperative patient care was designed and validated by anesthesia residents and staff. Following 2-week to 1-month baseline data collection, each anesthesiologists and anesthesia residents in participating hospitals were asked to implement the safe-anesthesia checklist to improve practice over another 2-week to 1-month period. The checklist consists of an oral confirmation and closed-loop communication between the primary anesthesiologist and the replacement anesthesiologist. Evaluation of the effect of implementation of a standardized checklist during anesthesia care handover on patient safety during follow-up.
Study NCT01926782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for alirocumab)
Description: Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Study NCT01926782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Study NCT01926782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Study NCT01926782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
Study NCT01926782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin
Description: Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
Study NCT03177083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon beta-1a
Description: SC every 2 weeks
Study NCT03177083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon beta-1a
Description: Per Summary of Product Characteristics (SMPC)
Study NCT03177083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon beta-1b
Description: Per SMPC
Study NCT02424526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: home-based treadmill training
Description: the child will walk on a pediatric treadmill with the help of the parent/caregiver and with weekly supervision of a physical therapist
Study NCT02424526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Study NCT01472497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: pioglitazone (15mg) once a day for 24 weeks
Study NCT00778037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine hydrochloride 10 mg tablet
Study NCT00778037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine hydrochloride 10 mg tablet
Study NCT02296398 — intervention group
Intervention type: DRUG
Intervention: Romidepsin
Description: Received romidepsin per standard of care or through a clinical trial for more than one cycle
Study NCT02465073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NXTSC wound gel
Description: Subjects will receive NXTSC wound gel only.
Study NCT02465073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NXTSC wound gel plus Standard of Care
Description: Subjects will be randomized to the NXTSC wound gel plus Standard of Care of only.
Study NCT02465073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Group
Description: Subjects will receive Standard of Care only.
Study NCT01999283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Group Exercise
Description: Yoga poses and postures modified to diminish stress on the cervical region and improve flexibility. Breathing and mind-body focus to address stress-related discomfort. A general Hatha yoga style will be used with components from Ashtanga Yoga. Intensity and range of motion will be progressively increased as tolerated.
Study NCT01999283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Group Mat Exercise
Description: The Pilates mat exercises focus on both spinal muscle activation and stability, progressive endurance of the stabilizing muscles with arm and leg challenges and dynamic mobility. The exercises are progressed from more supported to anti-gravity position, slow increases in arm weights and flexibility.
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 1
Description: Dose 1 of sevoflurane
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 2
Description: Dose 2 of sevoflurane
Study NCT00522587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed sevoflurane dose 3
Description: Dose 3 of sevoflurane